{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:21:19Z","timestamp":1791181279737,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1016\/j.revmed.2004.06.017","type":"journal-article","created":{"date-parts":[[2004,8,5]],"date-time":"2004-08-05T15:43:53Z","timestamp":1091720633000},"page":"119-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Thalidomide\u00a0: m\u00e9canismes d'action et indications en h\u00e9matologie"],"prefix":"10.1016","volume":"26","author":[{"given":"X.","family":"Leleu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.B.","family":"Micol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Guieze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Berthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Kuhnovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Terriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Facon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2004.06.017_BIB1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/8371","article-title":"Thalidomide on the comeback trail","volume":"5","author":"Hales","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.revmed.2004.06.017_BIB2","first-page":"2555","article-title":"Kindliche missblidungen nach medikament-einnahme wahrend der gravidtat?","volume":"86","author":"Lenz","year":"1961","journal-title":"Disch Med Wochenschr"},{"key":"10.1016\/j.revmed.2004.06.017_BIB3","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(61)90927-8","article-title":"Thalidomide and congenital anomalies","volume":"2","author":"Mc Bride","year":"1961","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2004.06.017_BIB4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/(SICI)1096-9926(199612)54:6<273::AID-TERA1>3.0.CO;2-#","article-title":"Thalidomide, a current teratogen in South America","volume":"54","author":"Castilla","year":"1996","journal-title":"Teratology"},{"key":"10.1016\/j.revmed.2004.06.017_BIB5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/tera.1420380307","article-title":"Proposed mechanisms of action in thalidomide embryopathy","volume":"38","author":"Stephens","year":"1988","journal-title":"Teratology"},{"key":"10.1016\/j.revmed.2004.06.017_BIB6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/8466","article-title":"Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity","volume":"5","author":"Parman","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.revmed.2004.06.017_BIB7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0149-2918(03)80085-1","article-title":"Thalidomide: a review of approved and investigational uses","volume":"25","author":"Matthews","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.revmed.2004.06.017_BIB8","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1211\/0022357001774660","article-title":"Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man","volume":"52","author":"Eriksson","year":"2000","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(05)74905-9","article-title":"Thalidomide in toxic epidermal necrolysis","volume":"353","author":"Klausner","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2004.06.017_BIB10","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","article-title":"Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications","volume":"15","author":"Gupta","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2004.06.017_BIB11","first-page":"92","article-title":"New insights into the pharmacological and toxicological effects of thalidomide","volume":"6","author":"Meierhofer","year":"2003","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1016\/j.revmed.2004.06.017_BIB12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0162-3109(95)00050-X","article-title":"Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade","volume":"31","author":"Geitz","year":"1996","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.revmed.2004.06.017_BIB13","first-page":"1105","article-title":"Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide","volume":"47","author":"Settles","year":"2001","journal-title":"Cell Mol Biol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB14","first-page":"177","article-title":"Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations","volume":"46","author":"Zwingenberger","year":"1995","journal-title":"J Inflamm"},{"key":"10.1016\/j.revmed.2004.06.017_BIB15","first-page":"320","article-title":"Retionids enhance monocyte\/endothelium interaction","volume":"89","author":"Barkley","year":"1987","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB16","first-page":"641a","article-title":"Thalidomide analogs IMiDs inhibit expression of cyclooxygenase-2 in multiple myeloma cell line and LPS stimulated PBMCs","volume":"98","author":"Payvandi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB17","first-page":"4629","article-title":"Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases","volume":"60","author":"Attiga","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.revmed.2004.06.017_BIB18","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a therapeutic target in multiple myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.revmed.2004.06.017_BIB19","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.4049\/jimmunol.159.10.5157","article-title":"Inhibition of IL-12 production by thalidomide","volume":"159","author":"Moller","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/08923979609007110","article-title":"Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells","volume":"18","author":"Shannon","year":"1996","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB21","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1590\/S0100-879X1997001000010","article-title":"Thalidomide protects mice against LPS-induced shock","volume":"30","author":"Moreira","year":"1997","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.revmed.2004.06.017_BIB22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0162-3109(99)00041-7","article-title":"Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide","volume":"43","author":"Dunzendorfer","year":"1999","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.revmed.2004.06.017_BIB23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11926-000-0025-7","article-title":"The Th1\/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide","volume":"2","author":"Oliver","year":"2000","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.revmed.2004.06.017_BIB24","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB25","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2004.06.017_BIB26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jcp.1041610118","article-title":"Interaction of high-molecular-weight basic fibroblast growth factor with endothelium: biological activity and intracellular fate of human recombinant M(r) 24,000\u00a0bFGF","volume":"161","author":"Gualandris","year":"1994","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB27","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood.V93.9.3064.409k07_3064_3073","article-title":"Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma","volume":"93","author":"Vacca","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB28","first-page":"3111","article-title":"Prognostic value of bone marrow angiogenesis in multiple myeloma","volume":"6","author":"Rajkumar","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.revmed.2004.06.017_BIB29","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2004.06.017_BIB30","first-page":"M55","article-title":"The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance","volume":"1470","author":"Mayo","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.revmed.2004.06.017_BIB31","doi-asserted-by":"crossref","first-page":"22382","DOI":"10.1074\/jbc.M100938200","article-title":"Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity","volume":"276","author":"Keifer","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.revmed.2004.06.017_BIB32","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.4049\/jimmunol.168.6.2644","article-title":"Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester","volume":"168","author":"Majumdar","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB33","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0190-9622(84)80458-2","article-title":"Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes","volume":"11","author":"Barnhill","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB34","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB35","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB36","first-page":"1180","article-title":"Characterization of signaling cascades triggered by human interleukin-6 vs Kaposi's sarcoma-associated herpes virus-encoded viral interleukin-6","volume":"6","author":"Hideshima","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.revmed.2004.06.017_BIB37","first-page":"473a","article-title":"IGF-1-induced activation of NF-kB and upregulation of intracellular anti-apoptotic proteins in human multiple myeloma cells: therapeutic implications","volume":"98","author":"Mitsiades","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB38","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB39","first-page":"97","article-title":"Clinique, bilan, classification et valeur pronostique","volume":"4","author":"Moreau","year":"2002","journal-title":"Oncologie"},{"key":"10.1016\/j.revmed.2004.06.017_BIB40","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/cpt196563292","article-title":"Thalidomide (N-phthalidoglutarimide) in the treatment of advanced cancer","volume":"6","author":"Olson","year":"1965","journal-title":"Clin Pharmacol ther"},{"key":"10.1016\/j.revmed.2004.06.017_BIB41","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0037-1963(01)90017-4","article-title":"Thalidomide in the management of multiple myeloma","volume":"38","author":"Barlogie","year":"2001","journal-title":"Semin Hematol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB42","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase two study of 169\u00a0patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB43","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.thj.6200175","article-title":"Thalidomide in patients with advanced multiple myeloma: a study of 83\u00a0patients-report of the Intergroupe Francophone du Myelome (IFM)","volume":"3","author":"Yakoub-Agha","year":"2002","journal-title":"Hematol J"},{"key":"10.1016\/j.revmed.2004.06.017_BIB44","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood-2002-05-1527","article-title":"Efficacy of a low dose of thalidomide in advanced multiple myeloma","volume":"100","author":"Leleu","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/sonc.2002.34075","article-title":"Low-dose thalidomide in myeloma: efficacy and biologic significance","volume":"29","author":"Durie","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archderm.1994.01690010070009","article-title":"Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42\u00a0patients","volume":"130","author":"Ochonisky","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB48","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood-2002-01-0335","article-title":"Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy","volume":"100","author":"Zangari","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB49","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB50","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB51","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1200\/JCO.2003.07.200","article-title":"Treatment of plasma cell dyscrasias with thalidomide and its derivatives","volume":"21","author":"Dimopoulos","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.revmed.2004.06.017_BIB52","article-title":"Thalidomide plus CED-chemotherapy in patients with poor prognosis multiple myeloma","volume":"94","author":"Moehler","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB53","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bmt.1704173","article-title":"Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma","volume":"32","author":"Ghobrial","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.revmed.2004.06.017_BIB54","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","article-title":"Thalidomide as initial therapy for early-stage myeloma","volume":"17","author":"Rajkumar","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2004.06.017_BIB55","first-page":"2210","article-title":"Bone marrow angiogenesis in 400\u00a0patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis","volume":"8","author":"Rajkumar","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.revmed.2004.06.017_BIB56","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3816\/CLM.2003.n.005","article-title":"Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (Al) amyloidosis","volume":"3","author":"Seldin","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.revmed.2004.06.017_BIB57","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/sonc.2003.50071","article-title":"Angiogenesis in Waldenstrom's macroglobulinemia","volume":"30","author":"Rajkumar","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB58","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/sonc.2003.50079","article-title":"Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone","volume":"30","author":"Dimopoulos","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB59","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1365-2141.2002.03810.x","article-title":"Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report","volume":"119","author":"Wilson","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB60","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/sj.leu.2403058","article-title":"Thalidomide therapy induces response in relapsed mantle cell lymphoma","volume":"17","author":"Damaj","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2004.06.017_BIB61","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2141.1992.tb08905.x","article-title":"Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: an immunomorphometric study on trephine biopsies of the bone marrow","volume":"80","author":"Thiele","year":"1992","journal-title":"Br J Haematol"},{"issue":"suppl.1","key":"10.1016\/j.revmed.2004.06.017_BIB62","first-page":"116a","article-title":"Elevated VEGF serum levels in idiopathic myelofibrosis","volume":"94","author":"Di Raimondo","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB63","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/blood.V51.2.189.189","article-title":"Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis","volume":"51","author":"Jacobson","year":"1978","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB64","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2141.1997.292671.x","article-title":"Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis","volume":"97","author":"Martyre","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB65","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2004.06.017_BIB66","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","article-title":"A phase two trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia","volume":"101","author":"Mesa","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB67","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/sj.leu.2402596","article-title":"Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study","volume":"16","author":"Piccaluga","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2004.06.017_BIB68","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2141.2002.03443.x","article-title":"Thalidomide treatment in myelofibrosis with myeloid metaplasia","volume":"117","author":"Elliott","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB69","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S1470-2045(03)00999-9","article-title":"Thalidomide: no benefit in myelofibrosis with myeloid metaplasia","volume":"4","author":"Bonn","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB70","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1385\/MO:19:2:79","article-title":"Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia","volume":"19","author":"Merup","year":"2002","journal-title":"Med Oncol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB71","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB72","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0145-2126(99)00094-6","article-title":"Apoptosis and its significance in MDS: controversies revisited","volume":"23","author":"Yoshida","year":"1999","journal-title":"Leuk Res"},{"key":"10.1016\/j.revmed.2004.06.017_BIB73","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1182\/blood.V97.5.1427","article-title":"Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes","volume":"97","author":"Bellamy","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB74","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/cncr.10900","article-title":"Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes","volume":"95","author":"Aguayo","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2004.06.017_BIB75","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.bjc.6693515","article-title":"Angiogenesis in myelodysplastic syndromes","volume":"81","author":"Pruneri","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.revmed.2004.06.017_BIB76","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0145-2126(02)00036-X","article-title":"Thalidomide in the treatment of myelodysplastic syndrome with fibrosis","volume":"26","author":"Tsirigotis","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.revmed.2004.06.017_BIB77","first-page":"273b","article-title":"Combination of thalidomide and Enbrel for the treatment of patients with myelodysplastic syndromes (MDS)","volume":"98","author":"Raza","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB78","first-page":"273b","article-title":"Combination of thalidomide with pentoxifylline, ciprofloxacin and dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS)","volume":"98","author":"Raza","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB79","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2141.2003.04252.x","article-title":"Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha","volume":"121","author":"Steurer","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB80","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.11180","article-title":"A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome","volume":"97","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2004.06.017_BIB81","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood.V95.1.309","article-title":"Evidence of increased angiogenesis in patients with acute myeloid leukemia","volume":"95","author":"Hussong","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB82","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.V99.3.834","article-title":"Efficacy and safety of thalidomide in patients with acute myeloid leukemia","volume":"99","author":"Steins","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.06.017_BIB83","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2141.2000.01835.x","article-title":"Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug","volume":"108","author":"Kneller","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB84","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4065\/75.9.897","article-title":"Thalidomide in the treatment of relapsed multiple myeloma","volume":"75","author":"Rajkumar","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.revmed.2004.06.017_BIB85","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2141.2000.01983.x","article-title":"Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma","volume":"109","author":"Juliusson","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB86","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0093-7754(01)90029-6","article-title":"Thalidomide in refractory and relapsing multiple myeloma","volume":"28","author":"Blade","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB87","first-page":"408","article-title":"Salvage therapy with thalidomide in patients with advanced relapsed\/refractory multiple myeloma","volume":"87","author":"Tosi","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2004.06.017_BIB88","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4065\/78.1.34","article-title":"Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma","volume":"78","author":"Kumar","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.revmed.2004.06.017_BIB89","first-page":"399","article-title":"Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma","volume":"86","author":"Palumbo","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2004.06.017_BIB90","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1023\/A:1011132808904","article-title":"Thalidomide and dexamethasone combination for refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.revmed.2004.06.017_BIB91","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","article-title":"Thalidomide and dexamethasone for resistant multiple myeloma","volume":"121","author":"Anagnostopoulos","year":"2003","journal-title":"Br J Haematol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866304002413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866304002413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:08:42Z","timestamp":1759334922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866304002413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S0248866304002413"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2004.06.017","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thalidomide\u00a0: m\u00e9canismes d'action et indications en h\u00e9matologie","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2004.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}